Healx vs Insitro

Insitro has a disclosed valuation of $2.2B, while Healx's valuation is not publicly available, making a direct size comparison difficult. Insitro employs 300 people.

Insitro has raised more in total funding at $743M, compared to Healx's $47M — a gap of $696M. Combined, the two companies have completed 3 known funding rounds.

Insitro holds the higher Awaira Score at 73/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 18-point gap that reflects meaningful differences in scale or traction.

Healx was founded by Tim Guilliams in 2014. Insitro was founded by Daphne Koller in 2018. Visit each company's profile on Awaira for a full founder biography.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. Insitro: Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data, predict drug efficacy and safety profiles, and optimize candidate selection across therapeutic areas including metabolic disease, oncology, and immunology. The company has raised $743 million across multiple funding rounds, achieving a valuation of $2.2 billion as of its Series C stage. This positions Insitro among well-capitalized AI healthcare startups addressing the structural inefficiencies in drug discovery. The company partners with pharmaceutical institutions to apply its technology to their pipelines, leveraging both internal discovery programs and collaborations. Insitro's competitive approach differs from pure software platforms by integrating experimental validation, reducing the translation gap between computational predictions and real-world drug performance. The company operates in a crowded but expanding market of AI drug discovery platforms competing against both established pharma AI initiatives and other venture-backed startups. Its growth trajectory reflects investor confidence in AI-enabled drug discovery models, though clinical validation remains ongoing for internally developed candidates. Insitro uniquely combines machine learning with integrated wet-lab capabilities rather than operating as pure software, bridging computational predictions to experimental validation.

Healx was founded first in 2014, giving it 4 years of additional market experience. Insitro was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Healx has approximately 1-50 employees, while Insitro has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and Insitro are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.